Immuneering Corp

IMRX

Immuneering Corp

IMRX

Insider Sentiment (TTM):

Last Purchase:2026-06-23Last Sale:2024-04-01Shares Purchased (TTM):82,374Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:24,526,871Shares Outstanding:64,658,809Institutional Ownership Pct.:37.93%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Common Class A	-	65	0	65	-36	36	0	1	0	30	0	0
Common Class B	-	0	0	0	0	0	0	0	0	0	0	0
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	41	47	129	228	26	36	36	45	60	66	59	68
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	0	5	0	5	26	29
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	0	0
Debt Securities Available For Sale Excluding Accru…	109	109	44	-	-	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	8	5	3	2	1	2	3	5	4	3	3	3
Assets Current	158	161	176	229	28	38	40	55	64	74	89	101
Debt Securities Available For Sale Excluding Accru…	33	42	44	-	-	-	0	-	-	-	-	-
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Goodwill	7	7	7	7	7	7	7	7	7	7	7	7
Finite Lived Intangible Assets Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	3	3	3	3	3	4	4	4	4	4	4	4
Other Assets Noncurrent	0	0	0	1	1	1	1	1	1	1	1	1
Assets	202	215	232	241	40	51	53	69	77	88	103	114
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	1	2	2	2	1	2	2	3	2	2	2
Accrued Liabilities Current	4	3	8	7	5	3	5	5	4	3	5	3
Other Liabilities Current	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	8	5	10	10	7	5	8	7	7	5	8	6
Liabilities Noncurrent
Operating Lease Liability Noncurrent	3	3	3	4	4	4	4	4	4	4	4	4
Liabilities	11	8	14	13	11	9	11	11	11	9	12	10
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity
Additional Paid In Capital	502	500	499	497	283	281	266	264	258	256	254	252
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	-	-	-	0	0	0	-0	-0	0
Retained Earnings Accumulated Deficit	-311	-294	-280	-269	-254	-239	-224	-206	-192	-178	-163	-148
Stockholders Equity	191	207	218	228	29	42	41	58	66	79	91	104
Liabilities And Stockholders Equity	202	215	232	241	40	51	53	69	77	88	103	114
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-17.25%	0.58%	-19.96%	-	-	-	-	-	-	-	-	-
2025	36.80%	182.40%	224.80%	71.12%	87.89%	113.35%	-3.32%	0.00%	-30.06%	-6.94%	13.32%	1.13%
2024	-10.90%	-17.95%	-20.51%	-10.48%	114.52%	62.10%	27.49%	36.84%	13.45%	-21.82%	-30.91%	29.09%
2023	-	-	-	-	-	-	59.04%	41.35%	18.46%	-58.54%	-70.73%	-76.10%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	19.47	32.45	17.50	24.00	3.70	7.48	5.28	7.99	9.39	14.38	11.35	17.89
Quick Ratio	18.47	31.50	17.16	23.84	3.52	7.02	4.82	7.32	8.81	13.77	10.92	17.30
Working Capital	149.87M	156.43M	166.17M	219.56M	20.24M	33.10M	32.08M	48.34M	56.90M	69.27M	81.24M	94.96M
Leverage & Debt
Debt to Equity	0.06	0.04	0.06	0.06	0.38	0.21	0.27	0.19	0.16	0.12	0.13	0.09
Debt Ratio	0.06	0.04	0.06	0.05	0.28	0.17	0.21	0.16	0.14	0.11	0.12	0.09
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.89	-0.84	-1.27	-1.58	-1.73	-1.74	-2.04	-1.95	-1.89	-1.84	-1.88	-1.76
Free Cash Flow Per Share TTM	-0.81	-0.77	-1.03	-0.91	-1.04	-1.51	-1.84	-1.28	-1.72	-1.72	-1.74	-2.17
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-12,328,770.77%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-11,348,063.96%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-99.96%
Net Income Growth (1Y)	-7.81%	-11.87%	-8.21%	7.63%	10.81%	14.03%	14.15%	12.46%	8.06%	5.77%	5.86%	-4.88%
EPS Growth (1Y)	-48.72%	-51.58%	-37.47%	-19.04%	-8.69%	-5.74%	8.19%	10.29%	4.40%	-4.78%	-1.70%	-14.21%
Valuation Metrics
P/E TTM	-5.64	-6.26	-5.17	-4.44	-1.95	-0.87	-1.08	-1.28	-0.68	-1.57	-3.91	-4.35
P/B TTM	1.69	1.65	1.33	1.22	4.19	1.29	1.59	1.29	0.57	1.08	2.31	2.16
P/S TTM	-	-	-	-	-	-	-	-	-	-	-	493,989.56
Market Cap	322.84M	340.75M	289.60M	277.69M	121.27M	54.01M	65.96M	74.31M	37.96M	84.88M	208.86M	224.77M
Enterprise Value	281.51M	293.43M	160.95M	50.13M	94.92M	18.14M	29.81M	29.10M	-21.77M	18.59M	149.46M	156.72M
Calculated Values
Free Cash Flow TTM	-52.67M	-49.92M	-45.50M	-35.97M	-37.46M	-53.65M	-55.08M	-38.06M	-51.12M	-50.39M	-49.31M	-63.63M
Net Debt	-41.32M	-47.32M	-128.65M	-227.56M	-26.36M	-35.87M	-36.14M	-45.21M	-59.73M	-66.29M	-59.41M	-68.04M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Purchase

Owner: Zeskind, Benjamin J.

Title: PRESIDENT AND CEO

Shares: 2,400

Price/Share: $4.56

Value: $10,944.00

Shares Owned: 2,315,252

Relationship: Director,Officer

Ownership: Direct

2026-06-15Purchase

Owner: Hall, Brett Matthew

Title: CHIEF SCIENTIFIC OFFICER

Shares: 6,035

Price/Share: $4.15

Value: $25,045.25

Shares Owned: 382,531

Relationship: Officer

Ownership: Direct

2026-01-16Purchase

Owner: Brakewood, Harold Eugene

Title: Chief Business Officer

Shares: 5,250

Price/Share: $4.76

Value: $24,990.00

Shares Owned: 11,050

Relationship: Officer

Ownership: Direct

2026-01-15Purchase

Owner: Hall, Brett Matthew

Title: CHIEF SCIENTIFIC OFFICER

Shares: 2,298

Price/Share: $4.57

Value: $10,501.86

Shares Owned: 376,496

Relationship: Officer

Ownership: Direct

2026-01-15Purchase

Owner: Schall, Thomas J.

Title: -

Shares: 21,645

Price/Share: $4.67

Value: $101,082.15

Shares Owned: 74,530

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Zeskind, Benjamin J.	Director,Officer	PRESIDENT AND CEO	Direct	Purchase	2,400	4.56	$10,944.00	2,315,252	4
2026-06-15	Hall, Brett Matthew	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Purchase	6,035	4.15	$25,045.25	382,531	4
2026-01-16	Brakewood, Harold Eugene	Officer	Chief Business Officer	Direct	Purchase	5,250	4.76	$24,990.00	11,050	4
2026-01-15	Hall, Brett Matthew	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Purchase	2,298	4.57	$10,501.86	376,496	4
2026-01-15	Schall, Thomas J.	Director	-	Direct	Purchase	21,645	4.67	$101,082.15	74,530	4
2026-01-13	Neufeld, Leah R	Officer	CHIEF PEOPLE OFFICER	Direct	Purchase	2,626	4.15	$10,897.90	25,970	4
2026-01-12	Feinberg, Peter	Director	-	Indirect	Purchase	20,000	4.35	$87,000.00	135,441	4
2025-10-03	Feinberg, Peter	Director	-	Direct	Purchase	7,500	6.67	$50,025.00	156,766	4
2025-10-01	Bookman, Michael	Officer	CHIEF LEGAL OFFICER, SECRETARY	Direct	Purchase	1,020	6.83	$6,966.60	4,870	4
2025-10-01	Neufeld, Leah R	Officer	CHIEF PEOPLE OFFICER	Direct	Purchase	800	6.38	$5,104.00	23,344	4
2025-10-01	Morales, Mallory	Officer	Chief Accounting Officer	Direct	Purchase	300	6.39	$1,917.00	27,533	4
2025-09-30	Feinberg, Peter	Director	-	Direct	Purchase	7,500	7.03	$52,725.00	149,266	4
2025-09-29	Feinberg, Peter	Director	-	Direct	Purchase	5,000	7.18	$35,900.00	141,766	4
2025-07-02	Zeskind, Benjamin J.	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Direct	Purchase	7,015	3.53	$24,762.95	2,312,852	4
2025-07-02	Hausman, Diana	Director	-	Direct	Purchase	2,500	3.60	$9,000.00	2,500	4
2025-07-02	Neufeld, Leah R	Officer	CHIEF PEOPLE OFFICER	Direct	Purchase	700	3.57	$2,499.00	10,729	4
2025-06-27	Schall, Thomas J.	Director	-	Direct	Purchase	9,500	3.66	$34,770.00	52,885	4
2025-06-23	Hall, Brett Matthew	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Purchase	6,007	2.43	$14,597.01	359,318	4
2025-06-20	Brakewood, Harold Eugene	Officer	Chief Business Officer	Direct	Purchase	1,900	2.53	$4,807.00	5,800	4
2025-06-18	Zeskind, Benjamin J.	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Direct	Purchase	21,000	2.39	$50,190.00	2,302,852	4
2025-06-18	Feinberg, Peter	Director	-	Direct	Purchase	25,000	2.53	$63,250.00	136,766	4
2025-06-17	Schall, Thomas J.	Director	-	Direct	Purchase	40,485	2.21	$89,471.85	43,385	4
2024-04-01	Cormorant, Private Health…	TenPercentOwner	-	Indirect	Sale	400,000	3.01	$1,204,000.00	2,895,273	4
2024-03-22	Schall, Thomas J.	Director	-	Direct	Purchase	2,900	2.55	$7,395.00	2,900	4
2024-03-22	Feinberg, Peter	Director	-	Direct	Purchase	25,000	2.55	$63,750.00	111,766	4
2024-03-22	Brakewood, Harold Eugene	Officer	Chief Business Officer	Direct	Purchase	3,900	2.57	$10,023.00	3,900	4
2024-03-22	Morales, Mallory	Officer	Chief Accounting Officer	Direct	Purchase	393	2.55	$1,002.15	8,278	4
2024-03-20	Hall, Brett Matthew	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Purchase	7,000	2.86	$20,020.00	345,896	4
2024-03-20	Neufeld, Leah R	Officer	CHIEF PEOPLE OFFICER	Direct	Purchase	3,818	2.88	$10,995.84	10,029	4
2024-03-19	Zeskind, Benjamin J.	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Direct	Purchase	20,000	2.77	$55,400.00	2,281,852	4
2024-03-19	Feinberg, Peter	Director	-	Direct	Purchase	25,000	2.56	$64,000.00	86,766	4
2024-03-18	Berman, Ann E	Director	-	Direct	Purchase	57,965	2.13	$123,465.45	67,465	4
2024-03-15	Cormorant, Global Healthc…	TenPercentOwner	-	Indirect	Sale	400,000	2.14	$856,000.00	3,295,273	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

37.93%

Inst. Shares: 24,526,871

Shares Outstanding: 64,658,809

2025-12-31

67.55%

Inst. Shares: 29,728,126

Shares Outstanding: 44,011,830

2025-09-30

61.05%

Inst. Shares: 24,218,267

Shares Outstanding: 39,670,095

2025-06-30

10.59%

Inst. Shares: 3,809,727

Shares Outstanding: 35,985,878

2025-03-31

10.75%

Inst. Shares: 3,820,319

Shares Outstanding: 35,529,652

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	24,526,871	64,658,809	37.93%
2025-12-31	29,728,126	44,011,830	67.55%
2025-09-30	24,218,267	39,670,095	61.05%
2025-06-30	3,809,727	35,985,878	10.59%
2025-03-31	3,820,319	35,529,652	10.75%
2024-12-31	3,452,504	29,981,565	11.52%
2024-09-30	3,526,080	29,841,883	11.82%
2024-06-30	8,635,053	29,653,355	29.12%
2024-03-31	10,900,049	29,370,357	37.11%
2023-12-31	12,641,460	28,416,558	44.49%
2023-09-30	13,226,799	29,266,309	45.19%
2023-06-30	13,522,797	28,647,450	47.20%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Immuneering Corp (IMRX) — SEC Financial Statements & Analysis

Immuneering Corp (IMRX) is a pharmaceutical preparations company, incorporated in DE. Immuneering Corp trades on Nasdaq as: IMRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Immuneering Corp reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.06x, a Price-to-Sales (P/S) ratio of 493989.56x (TTM), a Price-to-Book (P/B) ratio of 1.69x (TTM), at a market cap of $322.84M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.06x
P/S TTM: 493989.56x
P/B TTM: 1.69x
Market Cap: $322.84M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Immuneering Corp in?

Immuneering Corp (IMRX) operates in the Pharmaceutical Preparations industry.

What is IMRX's market cap?

Immuneering Corp (IMRX) has a market capitalization of $322.84M as of 2026-06-30.

What exchange does IMRX trade on?

Immuneering Corp (IMRX) trades on the Nasdaq.

Where is Immuneering Corp incorporated?

Immuneering Corp is incorporated in DE.